MDM2 and colorectal carcinoma: Therefore, to test the possibility that p53 activation is the key factor mediating the differential sensitivity of PTEN-/- and PTEN+/+ CRC cells to MDM2 inhibitor, we conducted p53 phenotype rescue experiments with a siRNA and a small molecule inhibitor of p53.